Cardiac effects of 6 months’ dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised-controlled, VASERA TRIAL

 

 

Short running title: Chronic cardiac effects of dietary nitrate

 

Luca Facontia,b,c, Charlotte Elizabeth Millsb,c,i, Virginia Govonib,c,ii, Haotian Gua,c, Steven Morantd, Benju Jianga,c, J. Kennedy Cruickshankb,c*, Webb James Andrewa,c*

 

a King’s College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, Department of Clinical Pharmacology, London, UK

b Department of Nutritional Sciences, School of Life Course Sciences, King’s College London, UK

c Biomedical Research Centre, Clinical Research Facility, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

d Medicines Monitoring Unit (MEMO), University of Dundee, UK

*The last two named are joint senior authors on this article

 

Current institutions:

i Food and Nutritional Sciences, University of Reading 

ii Barts and The London School of Medicine and Dentistry, Queen Mary University of London, VP-Health Offices, 2nd Floor Dean Rees House, Charterhouse Square, EC1M 6BQ, London

 

Conflict of interest/Disclosures: AJW holds shares in HeartBeet Ltd, who manufacture the beetroot juice used in this study. The other authors have stated explicitly that there are no conflicts of interest in connection with this article

 

 

Address for correspondence: Dr. Andrew J Webb: andrew.1.webb@kcl.ac.uk, +442071887188 ext 84700 (Senior Lecturer in Cardiovascular Clinical Pharmacology, King's College London, Department of Clinical Pharmacology, St. Thomas' Hospital London SE1 7EH)

 

Word Count: 2889

Total number of figures: 6

Number of tables: 2


Abstract

 

Aims: To explore whether long-term intervention with dietary nitrate ((NO3-), a potential tolerance-free source of beneficial vasoactive nitric oxide) and spironolactone (to oppose aldosterone’s potential deleterious cardiovascular effects) improve cardiac structure/function, independent of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure).

Methods: A sub-sample of participants in our double-blind, randomised, factorial-design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate-depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had trans-thoracic cardiac ultrasounds at baseline (n=105), 3 and 6 months (n=87) of intervention. Analysis was by modified intention-to-treat.

Results: Nitrate-containing juice (n=40) decreased left ventricular (LV) end diastolic volume: -6.3 mL (95% confidence intervals (CI) -11.1,-1.6), and end systolic volume: -3.2 mL (-5.9,-0.5), and increased end diastolic mass/volume ratio: +0.04 (0.00,0.07), relative to placebo juice (n=47). Spironolactone (n=44) reduced relative wall thickness compared to doxazosin (n=43): -0.01 (-0.02,-0.00). Whilst spironolactone reduced LV mass index relative to baseline: -1.48 g/m2.7 (-2.08,-0.88), there was no difference versus doxazosin: -0.85 g/m2.7 (-1.76,0.05). Spironolactone also decreased the E/A ratio: -0.12 (-0.19,-0.04) and increased S’ (a tissue-Doppler systolic function index) by 0.52 (0.05,1.0 cm/s). BP did not differ between the juices, or between the drugs.

Conclusions: 6 months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP-independent benefits on cardiac structure, extending mechanisms characterised in pre-clinical models of heart failure. Spironolactone’s effects on cardiac remodeling and systo-diastolic function whilst confirmatory, were independent of BP.

 

Key words: dietary nitrate, beetroot juice, echocardiography, cardiac remodelling, nitrate-nitrite-NO pathway, type 2 diabetes,

 

What is already known about this subject:

What this study adds:


Introduction

 

Type 2 Diabetes (T2DM) is a major risk factor for heart failure (HF) [1], with either reduced (HFrEF) or preserved ejection fraction (HFpEF) [2].  Patients with T2DM are particularly susceptible to increased LV volumes with drugs which cause fluid retention/increase pre-load, such as pioglitazone [3]. Conversely, simply lowering BP with losartan or atenolol in the LIFE study did not alter LV volumes in patients with diabetes [4].

 

Decreased production of nitric oxide (NO), a key regulator of vascular homeostasis, by NO synthases and/or decreased bioavailability of NO, (eg: due to excess reactive oxygen species, ROS), is implicated in vascular dysfunction in cardiovascular disease and T2DM [5], LV diastolic dysfunction [6], HF [7], and HFpEF [8]. However, standard approaches to supplement NO using organic nitrates, such as isosorbide mononitrate, lack benefit [9]. This loss of effect with chronic ingestion may be due to nitrate tolerance via decreased bioactivation, increased ROS production and endothelial dysfunction [10]. An alternative therapeutic approach may be via dietary inorganic nitrate (NO3-), as found in green leafy vegetables and beetroot [11]. Nitrate is reduced to nitrite (NO2-) via the entero-salivary circulation, and further reduced to NO in a hypoxia-dependent process. This “nitrate-nitrite-NO pathway” appears to lack these tolerance issues [12], suppress ROS [13] and reverse endothelial dysfunction [14], and has been extensively investigated clinically in studies up to 4-6 weeks, particularly for blood pressure (BP)-lowering [12][14-16][17]. By contrast, patients with T2DM appear to lack any effect of dietary nitrate on BP [17][18][19].  

 

However, we recently reported that dietary nitrate lowered central aortic systolic BP (–2.6 mm Hg [–4.5 to –0.75  PubMed mm Hg], (mean [95% CIs]) p=0.007), despite no effect on brachial BP, with the main haemodynamic findings of the current study [20]. This is consistent with our findings whereby inorganic nitrite acutely and selectively lowers central aortic pressure through a normoxia-dependent dilatory effect on conduit arteries (radial) in healthy volunteers [21, 22], and selectively dilates epicardial coronary arteries in patients undergoing coronary angiography [23].

 

Another important cause of heart failure in patients with T2DM is myocardial infarction due to coronary artery disease, with nitrite displaying a potential role  in coronary ischaemia-reperfusion injury (IRI) [24], acute ST-elevation myocardial infarction (STEMI) [25, 26], and remote ischaemic preconditioning (RIPC) [27, 28]. Moreover, Lefer and colleagues showed that chronic, 4-9 weeks’ oral sodium nitrite supplementation prevented the increases in end-diastolic volume (EDV) and end-systolic volume (ESV)) in murine models of IRI following left coronary artery occlusion  [29], and pressure-overload induced LVH with trans-aortic constriction  [7].

 

In contrast to NO-supplementation, mineralocorticoid antagonists are established treatments in HF and hypertension, combatting aldosterone-mediated deleterious cardiovascular effects [30], with 40 weeks’ spironolactone improving LV mass, arterial stiffness measured as pulse wave velocity (PWV), augmentation index, and aortic distensibility, in parallel with the reduction in BP, over in patients with stage 2-3 chronic kidney disease [31].

 

Given the potential for long-term dietary nitrate, and spironolactone, to improve cardiac structure or function, alongside, or independently of, any changes in arterial haemodynamics, we prospectively performed echocardiograms in a sub-sample of patients participating in our VaSera factorial RCT [20, 32], with the a priori intention of exploring these specific mechanisms independently of BP, following a chronic, 6 months’ treatment  with dietary nitrate (‘Beet-it®’ or ‘Beet-it Sport®’ beetroot juice), and/or spironolactone.

 

The primary hypothesis for the main study was that spironolactone, dietary nitrate, or both could reduce arterial stiffness, measured by PWV, as a treatment target formally independent of BP. We have recently reported that the primary outcome, change in arterial stiffness as cardio-ankle vascular index (CAVI), a nominally BP-independent measure, was not different between spironolactone and doxazosin, P=0.08 [20]. Also, and against the hypothesis, the secondary outcome, aortic PWV by arteriography adjusted for peripheral BP differences at baseline and BP change between trial arms from the trial’s start to end, was lower with doxazosin than spironolactone (P=0.045). Dietary nitrate had no effect on PWV.

 

 

 


Methods

 

Study Population

A sub-sample of patients (with, or at risk of, T2DM) who were consented and randomised in our VaSera factorial RCT had serial trans thoracic cardiac ultrasound performed during the course of the study. The study design and methods have previously been described in detail [32]. Briefly, participants with or at risk of T2DM were recruited from Guy’s and St Thomas’ Hospitals, London, UK and surrounding areas between 2013-2015. Inclusion criteria were age 18-80 years, clinically diagnosed T2DM or at risk of T2DM (as body mass index (BMI) ≥27 kg/m2, positive family history or glucose intolerance after 75g challenge), ability to understand and comply with the protocol. Exclusion criteria: interfering chronic illness, adverse reaction to either drug, known allergy to beetroot, eGFR <45 mL min-1, HbA1c >11% (97mM/M), pregnant, breast feeding or atrial fibrillation.

The results for the primary outcome – (arterial stiffness) are described above and have  been published separately [20].  The study was reviewed and approved by Central London National Research Ethics Service (NRES) and took place in the Clinical Research Facility (CRF) of St Thomas’s Hospital. (Clinical trial registration: ISRCTN25003627/ DOI 10.1186/ISRCTN25003627). After initial consent and screening/familiarisation, visit 1 (V1), and having met inclusion criteria, patients were invited to return for double randomisation (in blocks of 6) at visit 2 (V2), with simultaneous allocation to both types of intervention for each patient, therefore into 1 of 4 groups [32]; see Figure 1 for Study Flow Diagram. After cardiac and vascular measurements, treatments were: either spironolactone 12.5mg once daily for one week titrated to twice daily, OR doxazosin 2mg once daily for one week titrated to twice daily, AND either nitrate -containing beetroot juice (BEET-IT®, nitrate 4.5mmol/day) or placebo beetroot juice. The juices were identical in appearance, smell and taste, with the nitrate having been removed from placebo juice by ion exchange (nitrate ~0mmol/day). Following two check-up visits (V3 and V4; 2 and 8 weeks, respectively), cardiac and vascular measures were repeated at 3 months (V5). Then, provided there were no contraindications, medication doses were increased (to spironolactone 25mg twice daily or doxazosin 8mg twicedaily) and to more concentrated nitrate -containing beetroot juice (BEET-IT® Elite Sports Shot, ~11.2mmol nitrate/day, or matching placebo juice, ~0 mmol nitrate/day). The final visit (V6) was at 6 months’ post-randomisation, when V2 and V5 cardiovascular assessments were repeated.

Thus, in this factorial design, approximately half the patients were randomised to active, nitrate-containing beetroot juice, and the other half to the placebo nitrate-depleted juice (with no difference in BP expected, based on other studies of dietary nitrate in patients with T2DM described above). Also, half the patients were randomised to spironolactone, and the other half to doxazosin as control (expected to produce similar changes in BP from baseline, but no difference between the treatments). The factorial design is intended to permit determination of the independent effects of nitrate v placebo, and spironolactone v doxazosin, following testing for drug-dietary nitrate interactions for BP and for echocardiographic parameters.

 

Echocardiography: Echocardiography was added to the protocol and offered to as many of the patients as possible, to explore mechanisms related to standard cardiac structure and function assessments, in parallel with the key haemodynamic outcome measures of the main study.

 

Trans-thoracic cardiac ultrasound was performed using a GE Vivid 7 Ultrasound system. All measurements were performed by two expert operators and all images analysed by a single operator blinded to the intervention. Acquisitions were individually optimized for depth, gain, and frame rate to maximize image quality and minimize inconsistency in acoustic windows prior to analysis. Standard M-mode and 2D imaging was undertaken at rest. Images were saved in raw data format for offline analysis. Left atrial volume (LAV) was calculated by the ellipsoid method and subsequently normalized to body surface area to obtain left atrium volume index (LAVI). Recommendations of the American Society of Echocardiography and the European Association of Cardiovascular Imaging [33] were used to estimate left ventricular mass (LVM) which was indexed to height2.7, for LVM index (LVMI) to avoid systematic misclassification of cardiovascular risk in overweight and obesity - likely in these patients. Left ventricular ESV and EDV were measured using Simpson’s method and to estimate ejection fraction (EF). The ratio between LVM and EDV (mass/volume, M/V ratio) was calculated. Left ventricular (LV) systolic function was evaluated by peak systolic tissue Doppler imaging (TDI) of S’ wave (averaged between septal and later mitral annulus) and global longitudinal strain (GLS) assessed by 2-dimensional speckle tracking echocardiography. Diastolic function of the leftventricle was estimated by conventional Doppler mitral inflow (ratio of transmitral Doppler early (E) to late (A) filling velocity (E/A)) and tissue Doppler imaging (TDI) of mitral annulus (ratio of transmitral Doppler early filling velocity (E) to tissue Doppler early diastolic mitral annular velocity (E′) – (E/E’)), as per recommendations [34] as was the ratio E/E’ for evaluating LV filling pressure.

 

Statistical considerations

Analyses were conducted by our independent biostatistician (SM) modified intent-to-treat, consisting of all randomised patients except those with no outcome data at any follow up visit. Patients with missing data at some visits were included, and we assumed that data were missing at random (i.e. unrelated to the unobserved value). We used mixed effect models to estimate the effect of the interventions, and included gender, age, ethnicity (European, African-Caribbean, West African and other), a diagnosis of diabetes and the baseline value of the outcome as covariates. This was a pre-specified/prospectively-conducted, hypothesis-generating, exploratory mechanistic part of the main study.  Thus, we present least squares mean changes from baseline and differences between drugs and between juices averaged over both follow-up visits for each outcome, with 95% confidence intervals (95% CI), rather than as hypothesis-testing P-values, in accordance with the recent editorial, “Statistical reporting of clinical pharmacology research” [35]. 

 


Results

One hundred and five participants had echocardiograms at baseline (V2), of whom 87 (83%) also had follow-up data at V5 (3 months) and V6 (6 months); see Figure 2, CONSORT diagram. Participant details and baseline echo parameters in each treatment arm are shown in Table 1. Baseline LVMI (mean±SD) was 53±13.5g/m2.7; 52% met criteria for LV hypertrophy (LVH) [33], whilst 95% had normal LV filling pressure (average E/A 1±0.4, E/E’ 7.8±2.2).

Haemodynamic Parameters

Spironolactone and doxazosin both reduced systolic BP (SBP) by about 6 mmHg compared to baseline by with no difference between treatments (Table 2, Figure 3 (A-B)). Changes in diastolic BP (DBP) were also similar on each drug (~5 mmHg); see Figure 3 (C-D) with no change in heart rate (HR). There were no differences in brachial SBP, DBP or HR between nitrate-containing versus nitrate-depleted juice (Figure 4). No drug-dietary nitrate interactions were detected for BP or for echocardiographic parameters; therefore, the effects of the drugs and dietary nitrate were estimated from models with no interaction term.

Echocardiographic Morphological Parameters

Compared to placebo juice (n=47), nitrate-containing beetroot juice (n=40) decreased EDV: -6.33 mL (-11.1,-1.57) and ESV: -3.2 mL (-5.9,-0.5); see Table 2 and Figure 5. Also, EDV and ESV decreased relative to baseline on nitrate-containing beetroot juice: -4.77 mL (-8.10,-1.44) and -2.77 mL (-4.66,-0.89), respectively, but not on placebo juice (n=47): -1.56 mL (-1.67,4.80) and -0.40 mL (-1.43,2.22). The reduction in LVMI from baseline was similar between nitrate-containing and placebo juices, with no difference between interventions.  Therefore, the ratio between LV mass and volume – the M/V ratio, increased by 0.04 (0.00,0.07) between active and nitrate-containing beetroot juices. Relative to baseline, LAVI fell on active juice: -1.59 ml/m2 (-2.64,-0.54), but not placebo juice: -0.26 ml/m2 (-1.29,0.78); however, there was no difference between the interventions: -1.33(-2.83,0.17).

 

In contrast to nitrate, the only between-group difference in morphological parameters with spironolactone (n=44) was a marginal reduction in relative wall thickness (RWT): -0.01(-0.02,0.00) vs doxazosin (n=43); see Table 2. Whilst spironolactone reduced LVMI relative to baseline: -1.48 g/m2.7 (-2.08, -0.88), there was no difference versus doxazosin: -0.85 g/m2.7 (-1.76,0.05). Similarly, LAVI appeared to be reduced by doxazosin relative to baseline: -1.16 ml/m2 (-2.24,-0.07), but not versus spironolactone.

 

Echocardiographic Systo-Diastolic Function

Among parameters of systo-diastolic function, the E/A ratio fell on spironolactone from baseline: -0.07 (-0.12,-0.02), and versus doxazosin: -0.12 (-0.19,-0.04)); see Figure 6 (A-B).  The tissue Doppler systolic function index, S’, increased on spironolactone versus doxazosin, by 0.52 cm/s (0.05, 1.00); see Figure 6 (C-D).

The only change in systo-diastolic function parameters observed with nitrate-containing beetroot juice was a prolongation of the deceleration time (DT) by 19.50 ms (8.40, 30.60) and 19.74 ms (4.47,36.01) relative to baseline and nitrate-depleted juice, respectively.

 


Discussion

We found that 6 months’ intervention with dietary nitrate as beetroot juice may reduce LV volumes (EDV and ESV) compared to placebo nitrate-depleted juice. The lack of any change in LV mass by active juice suggests a favourable effect of nitrate on LV structure and possibly myocardial wall stress (since LV volumes were reduced, whilst BP was unaffected). In addition, spironolactone decreased RWT, suggesting a beneficial effect on myocardial remodelling, and improved parameters of systo-diastolic function (S’, E/A) compared to doxazosin. These effects were also independent of BP (which was not different between spironolactone and doxazosin).

 Nitrate’s chronic effect on reducing LV volumes have important implications for HFpEF, and builds on the beneficial acute actions of nitrate/nitrite recently demonstrated on exercise performance and left heart filling pressures (PCWP), in patients with HFpEF [36-39]. Indeed, across two randomised double-blind placebo-controlled studies by Borlaug and colleagues, one in 28 patients [37], the other in a subset of 52 of 98 patients with HFpEF [39], who were undergoing invasive haemodynamic exercise testing, sodium nitrite (either intravenous or nebulised-inhaled) acutely decreased aortic wave reflections (at rest), improved arterial compliance, elastance and central hemodynamics (during exercise), and left heart filling pressures (pulmonary capillary wedge pressure [PCWP]), compared to placebo [37]. However, no clinical data are available on the long-term effects of dietary nitrate on cardiac structure and function. This is a key question, given the problems of tolerance associated with organic nitrates. Therefore, the current study provides the most extensive evidence to date of long-term cardiac effects of dietary nitrate and has biological plausibility, building on the translational study of 9 weeks’ supplementation with oral nitrite showing decreased EDV and ESV versus placebo in the mouse model of pressure-overload induced LVH with trans-aortic constriction [7]. Regarding the specific changes in ventricular volumes in our study, it can be speculated that dietary nitrate-derived nitrite likely acts on ventricular pre-load by influencing venous dilatation [22, 40], and pressure; though since nitrate salts are also known to have diuretic activity, this could play a role. No direct measures of pre-load were collected here; however, changes in indirect parameters, such as ventricular volumes, as demonstrated with intravenous organic nitrate therapy [41]) support this. Indeed, previous invasive studies have used EDV to define LV pre-load [42, 43]. Moreover, the reduction in LV volumes, but not LVMI, resulted in an increased M/V ratio. This suggests a positive action on cardiac remodelling [44]and myocardial wall stress [45], with potential favourable prognostic implications [46].

In contrast to nitrate, ventricular volumes were not altered by spironolactone, which instead improved other structural and functional cardiac parameters. Spironolactone has previously been demonstrated to improve cardiac hypertrophy and remodelling in hypertensive patients [47], although this was not shown in patients with T2DM [48].  In our population, there was some evidence that spironolactone decreased RWT and LVMI, suggesting a direct action of spironolactone on cardiac remodelling (that was independent of BP). If confirmed, this finding would be relevant because cardiac remodelling is a prognostic factor for CV events - even in the absence of LVH [49].

Our results also suggest important differential actions of the two drugs on cardiac performance (S’ and E/A).  S’ is considered a sensitive TDI index of systolic function [50] which was increased by spironolactone compared with doxazosin.

Spironolactone has previously been found to have beneficial effects on diastolic function [51, 52]. In subclinical diabetic cardiomyopathy, spironolactone decreased conventional Doppler parameters (E/A), without affecting E/E’ [47], despite evidence of elevated LV diastolic filling pressure (E/E’ 14.3±7). We also observed a reduction in E/A ratio with spironolactone, with no change in E/E’, which was within the normal range at baseline. Therefore, the reduction in E/A may reflect an improvement in diastolic function that is not limited to alterations in pre-load, since other parameters sensitive to pre-load, such as EDV, ESV and LAVI were not affected by spironolactone, Table 2, (and neither were blood pressure or heart rate).  However, diastolic function is a complex phenomenon and a “single parameter” approach does not provide a comprehensive overview [34].

Overall, these results indicate that dietary nitrate may have BP-independent beneficial actions on myocardial remodelling over and above established effects of spironolactone. This could be explained by different mechanisms of action – mainly cardiac pre-load for dietary nitrate versus a direct anti-remodelling effect for spironolactone; although a direct action of nitrate/nitrite on the myocardium cannot be excluded and should be further investigated.

We acknowledge several limitations of our study: cardiac analysis was not the primary outcome of the Vasera trial and our analyses are therefore exploratory; the overall sample size was relatively small (87 patients with follow-up data); confidence intervals are therefore wide; follow up data was incomplete, and the mixed effects model may not adequately account for any bias this could have introduced.

 


Conclusion

Six months' dietary nitrate decreased LV volumes ~5%, representing sustained, BP-independent effects on cardiac structure, suggesting a beneficial action on cardiac remodelling, with potential consequences on CV prevention/treatment. Spironolactone independently decreased LV wall thickness and modified parameters of systo-diastolic function.

 

Acknowledgements:

The authors thank the research nurses at the Clinical Research Facility at St Thomas’ Hospital for their assistance in running the study and the patients who participated. We also thank Karen McNeill for managing the blinding and randomization of the interventions and Suzanne Barrett who worked as research administrator.

Source of funding: This work was funded by Fukuda Denshi Ltd. The research was supported by the National Institute for Health Research (NIHR) Clinical Research Facility at Guy’s & St Thomas’ NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

 

 

 

 

References

1.         Cavender MA, Steg PG, Smith SC, Jr., Eagle K, Ohman EM, Goto S, et al. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015;132(10):923 PubMed -31.

2.         Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2018;20(5):853-72.

3.         Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8:15.

4.         Gerdts E, Okin PM, Omvik P, Wachtell K, Dahlof B, Hildebrandt P, et al. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr Metab Cardiovasc Dis. 2009;19(5):306-12.

5.         Jin RC, Loscalzo J. Vascular Nitric Oxide: Formation and Function. J Blood Med. 2010;2010(1):147-62.

6.         Brooks BA, Franjic B, Ban CR, Swaraj K, Yue DK, Celermajer DS, et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab. 2008;10(9):739-46.

7.         Bhushan S, Kondo K, Polhemus DJ, Otsuka H, Nicholson CK, Tao YX, et al. Nitrite therapy improves left ventricular function during heart failure via restoration of nitric oxide-mediated cytoprotective signaling. Circ Res. 2014;114(8):1281 PubMed -91.

8.         Zamani P, French B, Brandimarto JA, Doulias PT, Javaheri A, Chirinos JA, et al. Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. The American journal of cardiology. 2016;118(12):1855-60.

9.         Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. The New England journal of medicine. 2015;373(24):2314-24.

10.       Omar SA, Artime E, Webb AJ. A comparison of organic and inorganic nitrates/nitrites. Nitric Oxide. 2012;26(4):229 PubMed -40.

11.       Lidder S, Webb AJ. Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway. British journal of clinical pharmacology. 2013;75(3):677-96.

12.       Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015;65(2):320 PubMed -7.

13.       Webb A, Ahluwalia A. Mechanisms of nitrite reduction in ischemia in the cardiovascular system: therapeutic potential. In: Ignarro L, editor. Nitric Oxide (Second Edition) Biology and Pathobiology. ISBN: 978-0-12-373866-0. London: Academic Press; 2010. p. 555-86.

14.       Velmurugan S, Gan JM, Rathod KS, Khambata RS, Ghosh SM, Hartley A, et al. Dietary nitrateimproves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study. The American journal of clinical nutrition. 2016;103(1):25-38.

15.       Khatri J, Mills CE, Maskell P, Odongerel C, Webb AJ. It is rocket science - why dietary nitrate is hard to 'beet'! Part I: twists and turns in the realization of the nitrate-nitrite-NO pathway. British journal of clinical pharmacology. 2017;83(1):129-39.

16.       Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008;51(3):784 PubMed -90.

17.       Shaltout HA, Eggebeen J, Marsh AP, Brubaker PH, Laurienti PJ, Burdette JH, et al. Effects of supervised exercise and dietary nitrate in older adults with controlled hypertension and/or heart failure with preserved ejection fraction. Nitric Oxide. 2017;69:78-90 PubMed .

18.       Gilchrist M, Winyard PG, Aizawa K, Anning C, Shore A, Benjamin N. Effect of dietary nitrate on blood pressure, endothelial function, and insulin sensitivity in type 2 diabetes. Free radical biology & medicine. 2013;60:89-97 PubMed .

19.       Shepherd AI, Gilchrist M, Winyard PG, Jones AM, Hallmann E, Kazimierczak R, et al. Effects of dietary nitrate supplementation on the oxygen cost of exercise and walking performance in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled crossover trial. Free radical biology & medicine. 2015;86:200-8.

20.       Mills CE, Govoni V, Faconti L, Casagrande ML, Morant SV, Webb AJ, et al. Reducing Arterial Stiffness Independently of Blood Pressure: The VaSera Trial. Journal of the American College of Cardiology. 2017;70(13):1683-4.

21.       Mills CE, Khatri J, Maskell P, Odongerel C, Webb AJ. It is rocket science - why dietary nitrate is hard to 'beet'! Part II: further mechanisms and therapeutic potential of the nitrate-nitrite-NO pathway. British journal of clinical pharmacology. 2017;83(1):140-51.

22.       Omar SA, Fok H, Tilgner KD, Nair A, Hunt J, Jiang B, et al. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscularconduit arteries and related selective actions on central blood pressures. Circulation. 2015;131(4):381 PubMed -9; discussion 9.

23.       O'Gallagher K, Khan F, Omar SA, Kalra S, Danson E, Cabaco AR, et al. Inorganic Nitrite Selectively Dilates Epicardial Coronary Arteries. Journal of the American College of Cardiology. 2018;71(3):363-4.

24.       Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci U S A. 2004;101(37):13683-8.

25.       Jones DA, Pellaton C, Velmurugan S, Rathod KS, Andiapen M, Antoniou S, et al. Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction. Circ Res. 2015;116(3):437 PubMed -47.

26.       Siddiqi N, Neil C, Bruce M, MacLennan G, Cotton S, Papadopoulou S, et al. Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). Eur Heart J. 2014;35(19):1255 PubMed -62.

27.       Nair A, Khan S, Omar S, Pei XQ, McNeill K, Chowienczyk P, et al. Remote ischaemic preconditioning suppresses endogenous plasma nitrite during ischaemia-reperfusion: a randomized controlled crossover pilot study. British journal of clinical pharmacology. 2017;83(7):1416-23.

28.       Rassaf T, Totzeck M, Hendgen-Cotta UB, Shiva S, Heusch G, Kelm M. Circulating nitrite contributes to cardioprotection by remote ischemic preconditioning. Circ Res. 2014;114(10):1601-10.

29.       Donnarumma E, Bhushan S, Bradley JM, Otsuka H, Donnelly EL, Lefer DJ, et al. Nitrite Therapy Ameliorates Myocardial Dysfunction via H2S and Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2)-Dependent Signaling in Chronic Heart Failure. Journal of the American Heart Association. 2016;5(8).

30.       Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92(2):175 PubMed -82.

31.       Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. Journal of the American College of Cardiology. 2009;54(6):505-12.

32.       Mills CE, Govoni V, Casagrande ML, Faconti L, Webb AJ, Cruickshank JK. Design and progress of a factorial trial testing the effect of spironolactone and inorganic nitrate on arterial function in people at risk of or with type 2 diabetes. Artery Research. 2015;12:48-53 PubMed .

33.       Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39 e14.

34.       Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314.

35.       Ring A, Schall R, Loke YK, Day S. Statistical reporting of clinical pharmacology research. British journal of clinical pharmacology. 2017;83(6):1159-62.

36.       Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015;131(4):371 PubMed -80; discussion 80.

37.       Borlaug BA, Koepp KE, Melenovsky V. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2015;66(15):1672-82.

38.       Eggebeen J, Kim-Shapiro DB, Haykowsky M, Morgan TM, Basu S, Brubaker P, et al. One Week of Daily Dosing With Beetroot Juice Improves Submaximal Endurance and Blood Pressure in Older Patients With Heart Failure and Preserved Ejection Fraction. JACC Heart Fail. 2016;4(6):428 PubMed -37.

39.       Reddy YNV, Andersen MJ, Obokata M, Koepp KE, Kane GC, Melenovsky V, et al. Arterial Stiffening With Exercise in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 2017;70(2):136-48.

40.       Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, et al. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation. 2008;117(5):670-7.

41.       Elkayam U, Roth A, Kumar A, Kulick D, McIntosh N, McKay CR, et al. Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation. The American journal of cardiology. 1987;60(13):1106-11.

42.       Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. Journal of the American College of Cardiology. 2012;59(5):442-51.

43.       Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4(1):23-36.

44.       Velagaleti RS, Gona P, Chuang ML, Salton CJ, Fox CS, Blease SJ, et al. Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: the Framingham Heart Study. Circ Cardiovasc Imaging. 2010;3(3):257-63.

45.       Khouri MG, Peshock RM, Ayers CR, de Lemos JA, Drazner MH. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Circ Cardiovasc Imaging. 2010;3(2):164-71.

46.       Fabiani I, Pugliese NR, La Carrubba S, Conte L, Antonini-Canterin F, Colonna P, et al. Incremental prognostic value of a complex left ventricular remodeling classification in asymptomatic for heart failure hypertensive patients. J Am Soc Hypertens. 2017;11(7):412 PubMed -9.

47.       Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricularmass and diastolic function in patients with essential hypertension. Hypertens Res. 2002;25(6):837 PubMed -42.

48.       Jellis CL, Sacre JW, Wright J, Jenkins C, Haluska B, Jeffriess L, et al. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2014;15(7):776-86.

49.       Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2004;43(4):731 PubMed -8.

50.       Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. Journal of the American College of Cardiology. 2007;50(7):591-6.

51.       Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA : the journal of the American Medical Association. 2013;309(8):781-91.

52.       Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart. 2013;99(5):320 PubMed -6.

 

 


Table 1: Baseline Clinical and Cardiac Parameters of the Study Population

 

Doxazosin

Spironolactone

Placebo Juice

Active Juice

Placebo Juice

Active Juice

Patients

n

27

16

20

24

Sex -female

n (%)

6 (22)

5 (31)

8 (40)

8 (33)

Diabetes -at risk

n (%)

11 (41)

6 (38)

6 (30)

12 (50)

Previous CV event

n (%)

1 ( 3.7)

2 (12.5)

2 (10.0)

2 (8.3)

Smoker

n (%)

3 (12.0)

2 (15.4)

2 (13.3)

1 (5.6)

Age (years)

mean (SD)

54.9 (13.8)

58.4 (14.7)

58.2 (9.9)

57.1 (13.2)

BMI- Kg/m2)

Mean (SD)

30.2 (5.1)

32.7 (6.5)

33.0 (4.2)

33.7 (5.2)

SBP (mmHg)

Mean (SD)

135.1 (16.8)

134.3 (16.6)

139.2(17.6)

138.3 (21.6)

DBP (mmHg)

Mean (SD)

79.4 (11.1)

80.7 (8.2)

79.8 (11.8)

83.1 (15.6)

HR (beat/min)

Mean (SD)

73.3 (14.4)

70.2 (11)

73 (13.1)

66.7 (10.4)

LAVI (ml/m2)

Mean(SD)

23.0 (8.4)

25.3 (8.6)

25.6 (9.8)

24.9 (6.9)

LVMI (g/m2.7)

Mean(SD)

52.7 (12.6)

50.9 (11.9)

54.1 (15.2)

51.8 (10.5)

RWT

Mean(SD)

0.401 (0.064)

0.389 (0.068)

0.403 (0.057)

0.373 (0.052)

EDV (ml)

Mean(SD)

127.4 (35.7)

138.4 (45.6)

127.6 (19.3)

134.7 (34.1)

ESV (ml)

Mean(SD)

53.6 (16.9)

63.9 (29.7)

55.3 (10.7)

57.5 (15.2)

Mass/Volume (g/ml)

Mean(SD)

0.96 (0.33)

0.81 (0.23)

0.88 (0.24)

0.81 (0.23)

E/A

Mean(SD)

1.00 (0.30)

0.98 (0.31)

1.09 (0.66)

0.94 (0.26)

DT (msec)

Mean(SD)

233.0 (51.6)

232.4 (59.9)

212.3 (59.0)

220.3(53.6)

E/E’

Mean(SD)

7.55 (2.16)

8.38 (2.70)

7.63 (2.29)

7.50 (2.23)

EF (%)

Mean(SD)

58.20 (3.1)

54.90 (5.3)

56.80 (4.2)

57.4 (3.7)

S’ (cm/s)

Mean(SD)

9.0 (1.6)

9.0 (1.7)

8.8 (2.1)

8.8 (1.2)

 

Table 1: Baseline clinical and cardiac parameters of the study population. Abbreviations: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), left atrium volume index to body surface area (LAVI), left ventricular mass index (LVMI), relative wall thickness (RWT), end-diastolic volume (EDV), end-systolic volume (ESV), ratio of transmitral Doppler peak early (E) to late (A) filling velocity (E/A), ratio of transmitral Doppler peak early filling velocity (E) to pulsed-wave tissue-Doppler imaging (TDI)-derived early mitral annular diastolic velocity (E′) – (E/E’), early transmitral deceleration time (DT), ejection fraction (EF), pulsed-wave TDI-derived mitral annular systolic velocity – a systolic function index (S'), global longitudinal strain (GLS).

 


Table 2: Haemodynamic and Echocardiographic Parameters

 

 

Active juice

(n=40)

Placebo juice

(n=47)

Active vs

placebo juice

Spironolactone

(n=44)

Doxazosin

(n=43)

Spironolactone vs

Doxazosin

Haemodynamic  parameters

SBP (mmHg)

-6.34 (-9.09,-3.59)

-6.57 (-9.41,-3.73)

0.23 (-3.77, 4.22)

-6.49 (-9.31,-3.67)

-6.42 (-9.20,-3.64)

-0.07 (-4.07, 3.93)

DBP (mmHg)

-5.06 (-6.80,-3.33)

-4.96 (-6.76,-3.17)

-0.10 (-2.63, 2.43)

-5.19 (-6.96,-3.42)

-4.84 (-6.59,-3.09)

-0.35 (-2.86, 2.16)

HR (bpm)

0.14 (-1.51, 1.79)

-0.94 (-2.65, 0.76)

1.08 (-1.33, 3.49)

-0.05 (-1.73, 1.63)

-0.76 (-2.41, 0.89)

0.71 (-1.67, 3.09)

Morphological parameters

LAVI (ml/m2)

-1.59 (-2.64, -0.54)

-0.26 (-1.29, 0.78)

-1.33 (-2.83, 0.17)

-0.69 (-1.69, 0.32)

-1.16 (-2.24, -0.07)

0.47 (-1.05, 1.99)

LVMI (g/m2.7)

-0.96 (-1.60, -0.32)

-1.16 (-1.75, -0.57)

0.20 (-0.68, 1.09)

-1.48 (-2.08, -0.88)

-0.63 (-1.28, 0.01)

-0.85 (-1.76, 0.05)

RWT

-0.00 (-0.01, 0.00)

-0.00 (-0.01, 0.00)

-0.00 (-0.01, 0.01)

-0.001 (-0.01, -0.00)

0.00 (-0.00, 0.001)

-0.01 (-0.02, -0.00)

EDV (ml)

-4.77 (-8.10, -1.44)

1.56 (-1.67, 4.80)

-6.33 (-11.1, -1.57)

-2.36 (-5.52, 0.79)

-0.85 (-4.26, 2.59)

-1.51 (-6.28, 3.25)

ESV (ml)

-2.77 (-4.66, -0.89)

0.40 (-1.43, 2.22)

-3.17 (-5.86, -0.48)

-1.52 (-3.31, 0.27)

-0.86 (-2.78, 1.07)

-0.67 (-3.37, 2.03)

Mass/Volume (g/ml)

0.01 (-0.01, 0.03)

-0.03 (-0.05, -0.00)

0.04 (0.00, 0.07)

-0.01 (-0.03, 0.02)

-0.01 (-0.03, 0.02)

0.00 (-0.03, 0.04)

Systo-diastolic function  parameters

E/A

-0.00 (-0.05, 0.10)

-0.03 (-0.07, 0.02)

0.02 (-0.05, 0.10)

-0.07(-0. 12, -0.02)

0.05 (-0.01, 0.10)

-0.12 (-0.19, -0.04)

DT (ms)

19.50 (8.40, 30.60)

-0.24 (-10.6, 10.08)

19.74 (4.47, 36.01)

11.32 (0.82, 21.82)

7.93 (-3.42, 19.26)

3.39 (-12.5, 19.25)

E/E’

0.26 (-0.15, 0.68)

-0.19 (-0.57, 0.19)

0.45 (-0.12, 1.02)

-0.13 (-0.53, 0.26)

0.21 (-0.21, 0.62)

-0.34 (-0.93, 0.24)

EF (%)

0.46 (-0.29, 1.21)